  | 
	
	 
 printable version
 
	List of Members of, and Advisor to, the International Health Regulations (2005)  Emergency Committee concerning Influenza Pandemic (H1N1) 2009
Members
Dr Lawson Ahadzie
		
  		
  		Former Head of Surveillance Department, Ghana Health Service/Ministry of Health, Accra, Ghana
(Dr Ahadzie's membership was suspended after the fifth Emergency Committee Meeting on becoming a WHO staff member)
 
Mr André Basse
		
  		
  		Counsellor, Embassy of Senegal, Paris, France 
Dr Muhammad Akbar Chaudhry
		
  		
  		Principal, Professor of Medicine, Fatima Jinnah Medical College, Lahore, Pakistan
(Dr Chaudry's membership commenced with the sixth Emergency Committee Meeting)
 
Dr Supamit Chunssuttiwat
		
  		
  		Senior Expert in Disease Control, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand 
Dr Nancy Cox
		
  		
  		Director, Influenza Division, Centers for Disease Control and Prevention, Atlanta, USA 
Dr Anthony Evans
		
  		
  		Chief, Aviation Medicine Section, International Civil Aviation Organization, Montreal, Canada 
Professor John Mackenzie
		
  		
  		Professor of Tropical Infectious Diseases, Division of Health Sciences, Curtin University, Perth, Australia 
Professor Arnold Monto
		
  		
  		Professor, Department of Epidemiology, University of Michigan, Ann Arbor, USA 
Dr Fernando Otaiza
		
  		
  		Coordinator, National Infection Control Program, Ministry of Health, Santiago, Chile 
Dr Rogelio Pérez Padilla
		
  		
  		Director General, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico City, Mexico 
Dr Wing Hong Seto
		
  		
  		Chief of Service, Department of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region, China 
Dr Masato Tashiro
		
  		
  		Director, Department of Viral Diseases and Vaccine Control, National Institute of Infectious Diseases, Tokyo, Japan 
 
Dr Claude Thibeault
		
  		
  		Consultant in Aviation Medicine and Occupational Health, Montreal, Canada 
Dr John Wood
		
  		
  		Principal Scientist, Division of Virology, National Institute for Biological Standards and Control, Herts, United Kingdom 
Professor Maria Zambon
		
  		
  		Head of Respiratory Virus Unit, Virus Reference Department, Health Protection Agency, Centre for Infection, London, United Kingdom  
Advisor to the Emergency Committee
Professor Neil Morris Ferguson
		
  		
  		Chair in Mathematical Biology, Department of Infectious Disease Epidemiology, Imperial College Faculty of Medicine, London, United Kingdom 
Declaration of Interests
Dr Nancy Cox
		
  		
  		Her public health and surveillance research unit at the US Centers for Disease Control & Prevention (CDC) receives financial support from IFPMA for activities of CDC as a WHO Collaborating Centre in the field of influenza vaccine research and virus isolation work. 
Professor Arnold Monto
		
  		
  		He has declared current and past consultancies in the field of pandemic and/or seasonal influenza for GSK, Novartis, Roche, Baxter and Sanofi. The remuneration for each of these consultancies is below US$10 000. In addition, his research unit at the University of Michigan has received a grant from Sanofi Pasteur for a clinical trial conducted in 2007-2008 on the comparative efficacy of inactivated and live attenuated influenza vaccines.  
Dr Claude Thibeault
		
  		
  		Since 2004, he is the Consultant Medical Advisor to International Air Transport Association.  
Dr John Wood
		
  		
  		His research unit at the National Institute for Biological Standards and Control (NIBSC), a centre of the UK Health Protection Agency, has performed contract research for Sanofi Pasteur, CSL, IFPMA, Novartis and Powdermed in the field of influenza vaccine research and development. 
Professor Maria Zambon
		
  		
  		The UK Health Protection Agency Centre for Infection receives funding from vaccine manufacturers, including Sanofi, Novartis, CSL, Baxter and GSK, for contract work in Dr Zambon's laboratory.  
Professor Neil Morris Ferguson (Advisor)
		
  		
  		He has acted as a consultant for Roche and GSK Biologicals (ceasing in 2007), with total remuneration from all such work being under US$7 000 in 2007. 
  
		
  		
  		The interests summarized above do not give rise to a conflict of interest such that the experts concerned should be partially or totally excluded from participation in the Emergency Committee.  However, following WHO's policy, they were disclosed within the Committee so that other members were aware of them. All other Members of the Emergency Committee declared no relevant interests. 
      
 
 |